In­cyte nabs ap­proval of top­i­cal rux­oli­tinib in atopic der­mati­tis, but gets slapped with JAK warn­ing

In­cyte has made a pret­ty pen­ny with its JAK in­hibitor rux­oli­tinib over the years, but on Tues­day the drug crossed a new thresh­old.

The FDA ap­proved a top­i­cal for­mu­la­tion of the drug for mild-to-mod­er­ate atopic der­mati­tis, In­cyte an­nounced Tues­day af­ter­noon, giv­ing the Wilm­ing­ton, DE-based com­pa­ny a new ar­row in its rux­oli­tinib quiver. The drug, which will be mar­ket­ed as Opzelu­ra, is the first top­i­cal JAK in­hibitor ap­proved in the US and is in­di­cat­ed for AD pa­tients aged 12 and up who strug­gle to con­trol their dis­ease on oth­er pre­scrip­tion creams.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER